ArticleCureus2025
A Case of BRAF-V600E-Positive Pulmonary Pleomorphic Carcinoma Successfully Treated With Dabrafenib and Trametinib Administered via a Percutaneous Endoscopic Gastrojejunostomy Tube for Ileus Caused by Small Intestinal Metastasis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review.Translational lung cancer research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of non-small cell lung cancer (NSCLC). It has a rapid progression and poor prognosis and is resistant to conventional chemotherapy. The efficacy of molecular-targeted drugs for patients with PPC with targetable driver mutations has been reported. However, most molecular-targeted drugs are administered orally, limiting their application in cases where oral administration is difficult. We report the case of a 78-year-old male patient diagnosed with stage IIA lung cancer. He underwent lobectomy and was pathologically diagnosed with PPC harboring a BRAF-V600E mutation. His lung cancer recurred two months postoperatively with multiple metastases, including those in the small intestine, which caused intussusception and ileus. Because the resected specimen from the small intestinal tumor resembled the histopathological results of the preoperative lung tissue, treatment with dabrafenib and trametinib could be effective. A percutaneous endoscopic gastrojejunostomy (PEG-J) tube was placed on the anal side of the intussusception site to depressurize intragastric pressure, allowing drug administration while decompressing the stomach. Treatment initiated for a few days improved abdominal symptoms, and computed tomography (CT) revealed tumor shrinkage. This is the first reported case of a patient with malignant intestinal obstruction successfully treated with targeted therapy drugs administered via a PEG-J tube, which is a viable method for patients with NSCLC with driver mutations who cannot take oral medications or via a nasogastric tube. Furthermore, therapies targeting driver mutations may be effective for patients with PPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.